EDINBURGH, Scotland and LONDON — September 3, 2025 — Leads & Copy — Resolution Therapeutics has announced the first patient has been dosed and cleared the safety period in its Phase I/II EMERALD study, evaluating RTX001, a first-in-class engineered Regenerative Macrophage Therapy (RMT) for patients with a history of decompensated liver cirrhosis. The study is now open for full enrollment in the UK and Spain.
RTX001 represents a breakthrough as the first-in-human administration of an engineered RMT for patients with end-stage liver disease.
According to Dr. Amir Hefni, CEO of Resolution Therapeutics, this represents a significant milestone in advancing RTX001 as a potential first-in-class treatment option for patients with end-stage liver disease.
The EMERALD study is a multi-center, single-arm, open-label study evaluating the safety and efficacy of RTX001 in patients with end-stage liver disease.
Professor Jonathan Fallowfield, Chair of Translational Liver Research and Principal Investigator at the University of Edinburgh, hopes that RTX001 can help prevent further clinical events in patients with decompensated cirrhosis.
Dr. Vijay Shah, Resolution Therapeutics Advisory Board Member, believes this treatment could help stabilize liver disease for the long term.
Vanessa Hebditch, Director of Communications & Policy at the British Liver Trust, is encouraged by the progress in advancing RTX001 as a novel treatment for liver disease.
The EMERALD study builds on results in the MATCH Phase I & II studies where non-engineered RMT was well tolerated.
Additional information on the EMERALD study can be found on www.clinicaltrials.gov, NCT identifier NCT06823713.
Resolution is hosting an R&D Webinar on Wednesday 17th September 2025.
Contact: Resolution Therapeutics, https://resolution-tx.com/
Source: Resolution Therapeutics
